Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring.

The landscape of hemophilia treatment has recently undergone a drastic transformation with the advent of novel therapies, including extended half-life factor concentrates, nonfactor therapies, rebalancing agents, and gene therapies. While these advancements have improved patient outcomes, they have introduced challenges in laboratory monitoring. Traditional assays such as prothrombin time, activated partial thromboplastin time, and 1-stage clotting assays may not accurately reflect the hemostatic status in patients receiving these new treatments. This article reviews the evolution of hemophilia therapies and the corresponding challenges in laboratory testing, emphasizing the need for updated monitoring strategies to ensure optimal patient management.